1. Home
  2. PCRX vs DHC Comparison

PCRX vs DHC Comparison

Compare PCRX & DHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

HOLD

Current Price

$22.58

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Diversified Healthcare Trust of Beneficial Interest

DHC

Diversified Healthcare Trust of Beneficial Interest

HOLD

Current Price

$6.85

Market Cap

1.8B

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
PCRX
DHC
Founded
2006
1998
Country
United States
United States
Employees
N/A
585
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.8B
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
PCRX
DHC
Price
$22.58
$6.85
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$37.60
$7.25
AVG Volume (30 Days)
801.0K
2.1M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
N/A
0.60%
EPS Growth
107.44
N/A
EPS
0.16
N/A
Revenue
$541,533,000.00
N/A
Revenue This Year
$9.77
$3.13
Revenue Next Year
$9.71
$7.00
P/E Ratio
$138.44
N/A
Revenue Growth
26.04
N/A
52 Week Low
$18.80
$2.00
52 Week High
$27.99
$7.66

Technical Indicators

Market Signals
Indicator
PCRX
DHC
Relative Strength Index (RSI) 51.00 50.18
Support Level $20.41 $3.93
Resistance Level $23.91 $7.64
Average True Range (ATR) 1.00 0.36
MACD -0.06 -0.09
Stochastic Oscillator 48.13 20.87

Price Performance

Historical Comparison
PCRX
DHC

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About DHC Diversified Healthcare Trust of Beneficial Interest

Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.

Share on Social Networks: